According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent sales milestone payments. Expected to close in the second half of 2026, the transaction transfers a dry eye disease treatment approved in the U.S., China, and Taiwan to a specialized ophthalmic player, allowing Viatris to streamline its portfolio.
Harrow, Inc. (NASDAQ:HROW)'s Q2 2026 results reflected accelerating operational momentum. Revenue jumped 60% sequentially and 11% year-over-year to $70.7 million, powered by flagship dry eye drug VEVYE ($29.4 million, up ~40% sequentially) alongside strong demand for IHEEZO ($15.6 million) and TRIESENCE. Despite posting a GAAP net loss of $17.3 million and negative Adjusted EBITDA of $1.2 million, the company reiterated its ambitious full-year guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA.
Holding $83.9 million in cash as of June 30, Harrow is positioning 2026 as an operational inflection point toward profitability. Viatris Inc. (NASDAQ:VTRS) operates at a vastly larger scale. In Q2 2026, Viatris delivered $3.8 billion in total revenues (up 5% reported and 3.5% operationally) and $1.2 billion in Adjusted EBITDA (up 8% operationally), prompting management to raise full-year guidance midpoints.
While VTRS reported a GAAP net loss of $118.8 million, this was driven by a $177.8 million non-cash impairment charge on the Tyrvaya asset divestment itself. Meanwhile, the firm generated $382 million in Q2 operating cash flow and returned roughly $550 million to shareholders, including $270 million in share repurchases. For Harrow, Inc. (NASDAQ:HROW), the bull case centers on commercial synergy.
Adding Tyrvaya builds one of North America's most comprehensive branded dry eye portfolios alongside VEVYE, absorbing Viatris's specialized sales team and projecting over $30 million in Tyrvaya revenue by 2027. The bear case lies in execution and balance sheet strain; spending $30 million upfront consumes over a third of Harrow's liquid cash while the company continues to post quarterly GAAP net losses. For Viatris Inc. (NASDAQ:VTRS), the bull case highlights disciplined capital allocation and robust free cash flow, shedding lower-margin or non-core assets to focus resources on higher-growth pipeline drivers like its newly approved contraceptive patch, Gwyn Lo.
The bear case reflects the ongoing drag of divestment-related non-cash charges on GAAP reporting and steady pricing pressures across legacy pharmaceutical portfolios. Institutional positioning shows contrasting trends heading into the second half of 2026. HROW saw slight hedge fund consolidation, with 22 funds holding positions in Q1 2026 compared to 24 funds in Q4 2025; notable holders include Persistent Asset Partners (Xin Huang) with 3,986 shares valued at $169,285.
Extract — continue reading at the source.
